Lord Ara Darzi - 09 Jun 2022 Form 4 Insider Report for Evelo Biosciences, Inc.

Reporting relationship: Director
Issuer ticker: N/A
Reported as of: 09 Jun 2022
Net transaction value: $0
SEC form: 4
Accepted by SEC: 13 Jun 2022, 16:38:43 UTC
Prior SEC filing: 31 May 2022
Source filing: View source filing
Reporting owner signature: /s/ Daniel S. Char, Attorney-in-Fact for Ara Darzi

Key filing fact

Lord Ara Darzi filed Form 4 for Evelo Biosciences, Inc. on 13 Jun 2022.

Key facts

This page summarizes Lord Ara Darzi's Form 4 filing for Evelo Biosciences, Inc..
2 reported transactions and 2 derivative rows are listed below.
Accepted by SEC: 13 Jun 2022, 16:38.

Change

Previous filing in this sequence was filed on 31 May 2022.
Current net transaction value: $0.

Research use

This tells you what this filing adds before you inspect full transaction and derivative tables.
You can trace every row back to the original SEC filing document.

Evidence

Filed on Form 4

Ownership activity is grounded in SEC Form 4 disclosures.

View source filing

Reported derivative securities

Options, warrants, convertible securities, or similar derivative positions disclosed in the filing.

EVLO transaction Derivative

Stock Option (Right to Buy)

Award

Transaction value: $0
Shares: +20,000
Change %
Price: $0.000000
Shares after: 20,000
Date: 09 Jun 2022
Ownership: Direct
Underlying class: Common Stock
Underlying amount: 20,000
Exercise price: $2.60
Footnotes: F1

EVLO transaction Derivative

Stock Option (Right to Buy)

Award

Transaction value: $0
Shares: +30,000
Change %
Price: $0.000000
Shares after: 30,000
Date: 10 Jun 2022
Ownership: Direct
Underlying class: Common Stock
Underlying amount: 30,000
Exercise price: $2.02
Footnotes: F2

^* marks a reported price that did not pass the local price check.

Additional SEC filing notes

Filing notes and footnotes

Explanation of responses 2 footnotes

Footnote F1

The option vests on the earlier of June 9, 2023 and the day immediately prior to the date of the next annual meeting of the Issuer's stockholders occurring after the date of grant.

Footnote F2

The option vests on the earlier of June 10, 2023 and the day immediately prior to the date of the next annual meeting of the Issuer's stockholders occurring after the date of grant.